SPT Screening in Irradiated Hereditary Retinoblastoma Survivors

Learn more about:
Related Clinical Trial
Deep Learning in Retinoblastoma Detection and Monitoring. Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma RB Liquid Biopsy Biorepository Topotecan and Melphalan for Retinoblastoma Effect of Anesthetic Drugs on Neurocognitive Function in Children With Retinoblastoma Requiring Multiple Anesthetic Exposure – Preliminary Study Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. Autonomic Reflexes During Intra-arterial Chemotherapy for Retinoblastoma Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study Topotecan Episcleral Plaque for Treatment of Retinoblastoma G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment PCI Imaging System in Pediatric Ophthalmology Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients Conservative Treatments of Retinoblastoma Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Photoscreening for Retinoblastoma RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients Studying Health Outcomes After Treatment in Patients With Retinoblastoma Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma Phase I Trial of Periocular Topotecan in Retinoblastoma Episcleral Topotecan for Treatment of Group D Retinoblastoma Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma? CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma Chemotherapy in Treating Patients With Retinoblastoma New Strategies to Detect Cancers in Carriers of Mutations in RB1 Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma Carboplatin Plus Vincristine in Treating Children With Retinoblastoma Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Quality of Life in Children Cured of Retinoblastoma Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma SPT Screening in Irradiated Hereditary Retinoblastoma Survivors Attention to Retinoblastoma Diagnosed in the Trauma Setting Carboplatin Periocular Injection for Retinoblastoma Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala Research on the Environment and Children’s Health: Retinoblastoma Intravitreal Injections of Melphalan for Retinoblastoma Efficacy Study of Lucentis in the Treatment of Retinoblastoma Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life Retinoblastoma Biomarker Study Cancer Biology of Retinoblastoma Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Intra-arterial Chemotherapy for Children With Retinoblastoma Molecular Analysis of Retinoblastoma

Brief Title

SPT Screening in Irradiated Hereditary Retinoblastoma Survivors

Official Title

Multicenter Implementation of MR Imaging Studies in Irradiated Hereditary Retinoblastoma Survivors for Assessment of the Value of Craniofacial MRI Screening for Early Detection of Second Craniofacial Primary Tumors and to Enhance Survival

Brief Summary

      Rationale: Hereditary retinoblastoma survivors have an increased risk to develop second
      primary tumors (SPT) at a later age (with the highest risk in their teens), especially when
      they have been irradiated for retinoblastoma. The investigators hypothesize that regular
      screening with magnetic resonance imaging (MRI) could lead to early detection of SPTs leading
      to improved survival.

      Objective: To evaluate the potential benefit of craniofacial MRI screening for early
      detection subclinical secondary cancers in patients previously irradiated for hereditary

      Study design: Prospective multicenter non-invasive screening study. The total study duration
      will be four years of screening plus five years of follow-up.

      Study population: Irradiated hereditary retinoblastoma patients 8-18 years old Main study
      parameters/endpoints: To evaluate the ability of craniofacial MRI for early detection of
      SPTs, the investigators will determine the sensitivity and specificity of MRI at detecting
      SPTs in irradiated hereditary retinoblastoma patients.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Included patients will undergo yearly craniofacial MRI for a period of 4 years.
      They will also be asked to fill out a psychological burden assessment form each visit. A
      potential risk of screening might be associated anticipatory anxiety, but screening also
      could be reassuring for patients and their parents; the investigators are not sure which will
      outweigh. False-positive results from MRI screening could lead to unnecessary further
      diagnostics leading to possible added anxiety and diagnostics (e.g., biopsies). However, this
      group of patients have a high risk of developing SPTs, with poor 5-year survival statistics.
      Early detection and therefore treatment of earlier stage (smaller) tumors, might therefore
      increase survival of this patient group.

Study Type


Primary Outcome

Diagnostic accuracy of MRI for the detection of second primary tumors in hereditary irradiated retinoblastoma

Secondary Outcome

 5-year survival




Magnetic resonance imaging


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 2014

Completion Date

October 2023

Primary Completion Date

October 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with a history of hereditary retinoblastoma

          -  Patients that have been treated with external beam radiotherapy for retinoblastoma

          -  Age of patients at the first MR scan: 8 years or older (≥8 years old), but only as
             soon as the MR scan can be performed without sedation or general anesthesia, and until
             and including 18 years of age (≤18 years old).

        Exclusion Criteria:

          -  MRI related exclusion criteria:

               -  Claustrophobia

               -  Foreign non MR compatible metal objects in the body

               -  Foreign incompatible metal objects in or close to the head

               -  Exclusion criterium for additional contrast sequences: Allergic reaction to
                  contrast administration in the past




8 Years - 18 Years

Accepts Healthy Volunteers



Jonas A Castelijns, PhD, +31204440814, [email protected]

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Amsterdam UMC, location VUmc



Study Sponsor

Jonas A Castelijns, PhD, Study Chair, Amsterdam UMC, location VUmc

Verification Date

December 2014